ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue I January 2026

Systemic Failures in Human Neuroscience Trials and How to Fix Them

Aditi Kaushik[1]*, Ujjwal Bhardwaj[2], Sushila Kaura[3]

[1]Department of Biotechnology, NIILM University, Kaithal, India

[2]Department of Pharmacology, Ram Gopal College of Pharmacy, Gurugram, India

[3]Department of Pharmacology, Atam Institute of Pharmacy, OSG University, Hisar, India

***Corresponding Author**

DOI: https://doi.org/10.51244/IJRSI.2026.13010155

Received: 01 February 2026; Accepted: 06 February 2026; Published: 10 February 2026

ABSTRACT

Clinical trials in neuroscience have resulted in significant improvements, but they have also revealed persistent flaws in safety assessment, participant consent, ethics, and post-trial device/technology governance. This review combines high-impact incidents, regulatory analyses, and empirical studies to identify recurring failure modes: incomplete preclinical translation resulting in catastrophic adverse events, inadequately informed consent (particularly for cognitively vulnerable participants), ethically fraught placebo/sham surgical designs, insufficient long-term follow-up and device maintenance, data governance and cybersecurity gaps, and underreporting of harms. We examine representative case studies (such as the TGN1412 cytokine storm, the BIA 10-2474 FAAH inhibitor neurotoxicity, arguments about sham surgery in deep brain stimulation, and device post-trial care failures) to demonstrate systemic causes and consequences. For each shortcoming, we propose specific solutions, including updated preclinical-to-human dose strategies, improved consent processes (layered consent and ongoing consent assessment), independent safety oversight for high-risk first-in-human studies, device stewardship policies for implanted neurotechnologies, and increased transparency and adverse-event reporting. To our knowledge, no thorough analysis has rigorously examined the linked ethical, technological, regulatory, and methodological flaws found in all types of human neuroscience clinical trials globally. The existing literature is compartmentalized, focusing on individual case studies, ethical issues, or device-specific failures. This is the first integrated framework that combines translational failures, consent vulnerabilities, sham surgery controversies, neurodevice stewardship gaps, data governance deficiencies, and post-trial obligations into a unified failure-mode taxonomy, backed up by cross-regional analysis and high-impact case data. The analysis closes with a recommended checklist and research agenda for making neuroscience studies safer, more ethical, and socially responsible.

Keywords: Neuroscience clinical trials; First-in-human studies; Neuroethics; Translational failure; Informed consent; Adverse event reporting; Neurotechnology; Safety monitoring

INTRODUCTION

Clinical neuroscience trials involving pharmacological drugs, implantable neurodevices, neuromodulation, gene therapy, and cell therapy seek to provide transformational treatments for a variety of neurological and mental illnesses. However, therapies that directly affect the central nervous system (CNS) pose distinct and significant dangers because they can alter cognition, behavior, identity, or homeostatic physiology. While such trials are critical for developing therapies for otherwise intractable conditions, a series of high-profile failures and unresolved ethical tensions highlight ongoing flaws in trial design, preclinical to clinical translation, informed consent, long-term stewardship of neural technologies, and transparency. For example, the first-in-human trial of the superagonistic monoclonal antibody TGN1412 resulted in a fast, life-threatening "cytokine storm" in all six healthy volunteers, a disastrous consequence that preclinical animal research had failed to foresee [1]. Similarly, the Phase I study of the small molecule BIA 10-2474, a fatty acid amide hydrolase (FAAH) inhibitor, resulted in severe, quickly escalating brain impairment and one death, although appearing to

a

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue I January 2026

be safe at lower dosages [2]. On the device and neurosurgical side, the use of invasive controls such as sham surgery (e.g., in deep brain stimulation, DBS, or cell transplant trials) continues to elicit heated ethical debate: while such designs may produce high-quality evidence, they impose non-negligible risks on control participants with no prospect of direct benefit [3]. Finally, post-trial obligations have received more attention, as many people receiving experimental brain implants face uncertain long-term maintenance, limited access to technical or clinical follow up, and the potential of device "abandonment" [4].

Despite these concerning precedents, existing guidelines and regulatory frameworks, including those based on the Declaration of Helsinki, ICH GCP, and other international and national standards, frequently fail to adequately address the complex challenges posed by CNS-acting therapies and neurotechnologies. The complexity of therapies, diversity among jurisdictions, and rapid innovation in neurotechnology increase these disparities. Given this context, there is an urgent need for a comprehensive review that integrates empirical evidence, regulatory analyses, case studies, and ethical considerations in order to systematically map recurring failure modes in neuroscience trials, identify root causes, and propose concrete, actionable reforms. Such a review, which explicitly includes drugs, devices, neuromodulation, and other interventions, is especially timely as neurotechnology expands at an unprecedented rate, and regulators, clinicians, scientists, and patients wrestle with the risks and promises of interventions that go deep into the essence of human brain function.

This paper aims to (1) characterize major types of trial failures and ethical deficiencies in neuroscience research; (2) present representative case studies that illustrate how and why these failures occur; (3) analyze systemic root causes, including translational, regulatory, ethical, and commercial pressures; and (4) propose a practical checklist and policy recommendations intended for researchers, sponsors, regulators, and institutional review boards to minimize

Historical and Regulatory Context

Modern research ethics originated in the aftermath of World War II atrocities. Following the Nuremberg trials of Nazi physicians in 1947, the Nuremberg Code was established, defining for the first time the need for voluntary, informed permission, protection from coercion, and risk minimization in human testing [5]. Following the tragedies of wartime abuses, there was an acknowledged need for universal ethical obligations in human research [6]. Building on these foundations, the Declaration of Helsinki (originally endorsed in 1964 by the World Medical Association WMA) expanded ethical principles to include clinical research with patients. This Declaration was later revised numerous times (most recently in 2024) to remain relevant as medical research advanced [7]. In 1979, the Belmont Report outlined the three key ethical principles Respect for Persons (autonomy), Beneficence, and Justice that have since supported legal frameworks for human-subject research, primarily in the United States but with global ramifications [8]. Recognizing the increasing complexity and globalization of clinical research, particularly multinational drug trials, regulators and stakeholders worked to standardize standards across jurisdictions. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) issued the ICH GCP Guideline (E6) in 1996, which was widely implemented beginning in 1997. GCP formalized trial design, conduct, monitoring, recording, and reporting requirements, assuring scientific integrity while also protecting participants' rights, safety, and wellbeing [9]. Many countries have since incorporated these suggestions into binding national rules or regulations overseen by local regulatory organizations [10].

While drug and biologic regulation progressed along similar lines, medical device oversight, particularly for high-risk or implanted devices, moved more slowly. For medical devices used in humans (including experimental devices), ISO 14155 specifies Good Clinical Practice for the design, conduct, recording, and reporting of clinical research involving human subjects for regulatory purposes. It was first published in 2003 and has since been updated on a regular basis, with the most recent (3rd) version released in 2020 [11]. Furthermore, risk management for devices is defined by the standard ISO 14971 (Application of Risk Management to Medical Devices), which was initially published in 1998 and was most recently updated in 2019. This standard involves systematic risk analysis, risk evaluation, control, and continual post-production review essential for monitoring the safety of medical and implantable devices [12]. In parallel, regulatory frameworks in several places were modified to include these device-specific criteria. For example, the international consensus (via bodies such as the International Medical Device Regulators Forum IMDRF, successor to earlier groups such as the GHTF) supports the adoption of ISO 14155 for device clinical

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue I January 2026

investigations, which contributes to global harmonization of device trial regulations [11]. However, the proliferation of neurotechnologies, such as implantable neurodevices, deep brain stimulation (DBS), brain-computer interfaces (BCIs), and neuromodulation systems, has revealed flaws in existing frameworks. Traditional GCP or device trial guidelines were primarily designed for conventional pharmaceuticals or devices, not interventions that directly interact with or influence the brain, or gather and preserve neural data. As a result, many rules fail to address specific ethical, long-term safety, data privacy, and identity threats. Scholars have advocated for specialized governance frameworks for neurological data, neuroprivacy, "neurorights," and the long-term stewardship of neural equipment [13].

Furthermore, regulatory and ethical enforcement varies greatly by jurisdiction. While ICH GCP and ISO standards provide globally accepted norms, not all nations consistently implement or legally enforce them; national regulatory frameworks frequently lag behind or differ, resulting in inconsistent protections, particularly in international or cross-border neuroscience research. This regulatory heterogeneity, combined with rapid technological evolution in neuro devices and neurotech, including AI-driven brain data analysis, creates systemic blind spots, particularly in areas such as long-term follow-up, post-trial device maintenance, data governance, and participant autonomy and identity. Given this context, it is clear that while ethical principles (originating in Nuremberg, Helsinki, Belmont, and CIOMS) and regulatory standards (ICH GCP, ISO 14155/14971) provide a necessary foundation, they are inherently insufficient for the next generation of CNS-acting drugs and neurotechnologies [11,12]. The mismatch between legacy frameworks and emerging neuroscientific interventions highlights the critical need for updated, neuro-specific regulatory and ethical guidelines addressing device stewardship, data privacy, long-term safety, informed consent under cognitive vulnerability, and equitable access.

This legal and historical background is crucial for understanding the repeated failure types translational problems, safety oversights, insufficient consent processes, post-trial requirements, and transparency gaps found in contemporary neuroscience studies. It also provides context for the suggestions that can be made for assessment, which range from neuroethics-focused institutional review boards (IRBs) to mandated long-term follow-up, public adverse-event registries, and strong device stewardship and data governance obligations. In this context, chronologically arranged Guidelines/Acts along with their enaction years and significance are being listed here in the Table 1 (Regulatory & Ethical Milestones) for the readers' reference.

Year	**Act/Code & Guidelines**	**Significance**
1906	Pure Food and Drugs Act (USA)	First federal law regulating safety of drugs; aimed at misbranding/adulteration.
1938	Federal Food, Drug, and Cosmetic Act (USA)	Required proof of safety before marketing; laid foundation for preclinical toxicology.
1947	Nuremberg Code	Established principles of voluntary consent, human experimentation ethics after WWII atrocities.
1962	Kefauver-Harris Amendments (USA)	Required proof of efficacy and safety; tightened clinical trial regulations.
1964	Declaration of Helsinki (WMA)	Ethical guidelines for biomedical research involving humans; introduced concepts of riskbenefit assessment and independent review.
Year	**Act/Code & Guidelines**	**Significance**
1974	National Research Act (USA) / Belmont Report (1979)	Created Institutional Review Boards (IRBs); formalized ethical principles: Respect for Persons, Beneficence, Justice.
1980s	Growth of Phase I and first-in-human trials	Early CNS drug trials begin; preclinical-tohuman translation emphasized.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue I January 2026

1996	ICH-GCP E6 (R1)	Harmonized Good Clinical Practice for drug trials internationally; emphasized design, safety, monitoring, informed consent.
2000s	FDA/EMA guidance on risk-based device trials	Defined regulatory pathways for neurodevices; emphasized pre-market safety testing.
2006	TGN1412 trial (UK)	First-in-human monoclonal antibody caused life threatening cytokine release; exposed limitations of preclinical models, dose-setting, and safety monitoring.
2010	CIOMS Guidelines 2016 (revision process started)	Updated international ethical guidance for biomedical research; highlighted vulnerability, informed consent, and justice.
2016	BIA 10-2474 Phase I trial (France)	Severe neurologic injury in healthy volunteers; prompted reassessment of CNS drug trial design and dose escalation.
2016-2020s	Rise of adaptive neurostimulation & BCIs	Ethical focus on sham surgery, iterative consent, device stewardship, neurorights, and data privacy.
2020	ISO 14155 (3rd edition)	Specific GCP guidance for clinical investigations of medical devices; includes safety, monitoring, and reporting.
2024	Declaration of Helsinki latest revision	Incorporated contemporary challenges: digital data, device research, privacy, long-term followup, iterative consent.
2020-2024	Emerging neurorights frameworks	Legal and ethical recognition of mental privacy, cognitive liberty, mental integrity; applies to BCIs and implantable neurodevices.

Table1. Regulatory and ethical milestones

Failure Modes in Trials

Clinical neuroscience, whether using innovative pharmacological agents, implanted neurodevices, or neuromodulation, has repeatedly revealed a set of systemic flaws. These failure patterns are typically mutually reinforcing, as poor preclinical translation raises risk in first-in-human studies, exacerbating issues with consent, monitoring, and long-term follow-up. The primary kinds of recurring failure modes along with supporting evidence are presented here.

Dose Setting & Predictive Limitations

One of the most notable and frequently discussed failures in neuroscience medication trials is the low predictive value of preclinical models, particularly when moving from animals (typically nonhuman primates or rodents) to humans. The controversial TGN1412 study (2006) highlights this: despite seemingly good preclinical safety data, healthy human volunteers had a severe, perhaps fatal cytokine release syndrome within hours of medication [14]. This finding demonstrated the limitations of animal models and highlighted the risk of presuming that nonhuman data can consistently predict human immunological or CNS responses. Similarly, the story of BIA 10-2474, a fatty-acid amide hydrolase (FAAH) inhibitor evaluated in a first-in-human Phase I study, demonstrated how inadequate pharmacological understanding and dose selection can lead to catastrophic failure. In that trial, dose escalation and multi-dose design were carried out without proper

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue I January 2026

staggered dosing, pharmacokinetic understanding, or adequate mechanistic basis, resulting in a quickly developing neurologic condition and one death [2]. These cases are representative of a larger trend: preclinical research frequently fails to provide robust, human-relevant data on immunologic, neurologic, or off-target effects; dose setting may lack conservative, sentinel participant approaches; and bridging studies (e.g., human ex vivo, biomarker, safety pharmacology) may be insufficient to justify first-in-man dosing.

Trial Design & Procedures

Closely connected to translational failures is the frequent under design of safety monitoring, escalation protocols, and stop criteria, especially in first-in-human and early phase trials. In the BIA 10-2474 trial, the adaptive doseescalation design allowed groups of volunteers to be dosed at short intervals (10 minutes apart in single-dose parts), whereas in the multi-dose escalation plan, higher dose groups began before adequate pharmacokinetic or pharmacodynamic data from previous dose levels were fully analyzed or disclosed. The lack of conservative "sentinel" dose and insufficient safety pause contributed significantly to the disastrous outcome [15]. Furthermore, in device and neuromodulation-based studies, safety monitoring techniques frequently underestimate long-term hazards associated with implantation, hardware malfunction, stimulation programming, battery failures, or the need for explantation. This problem is exacerbated when studies are completed and there is no clear plan for maintenance, follow-up, or accountability for adverse events, essentially shifting long-term risk to participants.

Informed Consent Challenges

In neuroscience trials, particularly those involving CNS acting medications or implantable neurodevices, the conventional pillars of informed consent (disclosure, capability, and voluntariness) are frequently under significant strain. Participants may have cognitive deficits, mental problems, or overestimate prospective benefits ("therapeutic misconception"), especially in trials involving novel neural treatments. Several analyses of neural device research have found that disclosure of atypical, uncertain long-term risks (e.g., identity changes, need for maintenance, device failure) is frequently insufficient; capacity assessment may be inadequate; voluntariness may be undermined by therapeutic hope, desperate disease burden, or external pressure [16]. These consent issues are worsened when protocols fail to include continuing, iterative consent procedures, such as reconsent as new risks or data surface, or periodic review of ability and understanding. Without such protections, consent may be nominal but ethically weak, especially among vulnerable neurological or psychiatric populations.

Ethical Conflicts

The gold standard randomized controlled trial (RCT) approach frequently uses placebo or sham controls. However, in neurosurgical contexts, such as trials utilizing deep brain stimulation (DBS) or other implanted therapies, sham surgery often consists of real surgical procedures (e.g., burr holes, anesthesia) that provide no therapeutic benefit. This creates an urgent ethical quandary: while fake surgery can improve scientific validity and reduce prejudice, it exposes control subjects to surgical risk in the absence of direct clinical benefit [17, 18]. Critics contend that such designs may undermine the commitment to minimize injury, particularly considering the intrusive nature of neurosurgery. Even when sham controls are methodologically justified, their use necessitates rigorous ethical review, robust consent mechanisms, and a disputed risk-benefit balance, particularly in populations with neuropsychiatric or sensitive illnesses. These ethical problems continue to be a major challenge for neurosurgical/neurodevice trials [19].

Post-trial Obligations

Post-trial duties are an unappreciated failure mode, particularly in trials of implanted neural devices. When a trial is over, participants who got a device may require continued care, such as hardware maintenance or replacement (e.g., battery changes), software updates, explantation (if requested), or continuous clinical follow up. However, many trial procedures lack a defined plan for post-trial stewardship, including no commitment to long-term support, maintenance cost coverage, or care infrastructure. This typically results in "abandonment," in which participants are saddled with high costs or a loss of advantage [20]. Furthermore, a sizable proportion of investigators in adaptive DBS/neural device trials state that post-trial access is not guaranteed. Inadequate funding, a lack of infrastructure, and a lack of clarity regarding long-term accountability remain important

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue I January 2026

impediments [21]. This situation violates fundamental ethical precepts. Once a volunteer has been implanted with a potentially life-changing device, the sponsor/investigator bears long-term clinical and financial obligation.

Data Privacy, and device specific Risks

With the next generation of neurotechnologies, adaptive neurostimulation systems, closed loop deep brain stimulators (aDBS), and brain-computer interfaces (BCIs), new dangers develop regarding data privacy, security, identification, and control over neural data. Because these devices frequently capture, store, and may transmit neurological data (or stimulation logs), there is a risk of unwanted access, data leakage, abuse, or "neurorights" violations (mental privacy, cognitive liberty, mental integrity) [22]. Researchers in adaptive DBS trials have specifically voiced concerns about data security and privacy. 91% express concern about third-party access, and many emphasize the need for strict controls, openness, and continuing informed consent about data collection and usage [23]. Furthermore, cybersecurity concerns exist, including the possibility of foreign meddling. For example, assessments of BCI security have revealed possible "neuronal cyberattacks" in which malicious software alters neural signals, potentially compromising brain function [24]. Furthermore, commercial neurotech frequently relies on proprietary hardware and software, with little assurance of long-term support, upgrades, or compatibility increasing the danger of device obsolescence, loss of functioning, or forced explantation if the manufacturer discontinues support. The combination of medical, ethical, and technical risks along with weak regulatory oversight in many jurisdictions renders data governance and device stewardship a critical but insufficiently addressed failure mode in contemporary and future neuroscience trials.

Together, these recurrent failure modes poor preclinical translation, inadequate safety design, weak consent, ethically fraught control designs, absent post-trial care, and insufficient data governance form a pattern. They reflect not just occasional errors, but structural vulnerabilities in the way neuroscience research and trial design currently operates. These vulnerabilities are especially acute because interventions act directly on the CNS with potential effects on cognition, behavior, identity, long-term mental health, and personal data. Furthermore, various failure modes combine. For example, a poorly predicted drug effect (preclinical failure) may cause acute harm; if consent was compromised, this harm violates autonomy; if safety monitoring was insufficient, risk increases; if long-term care is not guaranteed (post-trial), participants are vulnerable; and if neural data are mismanaged, privacy and identity may be jeopardized. Recognizing and properly resolving these failure patterns is thus critical not only for scientific validity or regulatory compliance, but also for the ethics, human rights, and social legitimacy of neuroscience as a field.

Key Case Studies

Neuroscience trials have consistently exposed systemic flaws through landmark instances. These stories present actual examples of the previously described failure modes, such as preclinical misprediction, insufficient safety monitoring, ethical issues, and insufficient post-trial commitments.

I The TGN1412 trial in the United Kingdom is possibly the best-known example of a catastrophic failure in first in-human drug testing. Despite seemingly excellent preclinical safety trials in non-human primates, six healthy volunteers had a severe cytokine release syndrome within hours of taking the initial dose, resulting in multiorgan failure and extended hospitalization [1]. The instance demonstrates animal models' shortcomings in predicting human immunological responses and highlights the dangers of insufficient sentinel dosage and overly aggressive cohort augmentation. This trial's analyses underscored the importance of conservative first-in-human procedures, rigorous preclinical pharmacology, independent data monitoring committees, and progressive dosage with enough observation periods.

II A second high-profile failure happened with BIA 10-2474; a fatty acid amide hydrolase inhibitor tested in a Phase I trial in France. Higher repeated doses resulted in serious brain damage, including one death [25]. Contributing problems were poor pharmacokinetic and pharmacodynamic understanding prior to dose increase, insufficient safety monitoring, and a lack of staggered dosing among individuals. The trial spurred a widespread rethinking of CNS-active medication development, notably the translation of preclinical findings into first-inhuman dosing and the ethical requirement to protect participants in early-phase trials.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue I January 2026

III Sham-controlled surgical trials, particularly in DBS studies for Parkinson's disease and psychiatric problems, highlight ethical challenges in invasive neuroscience research. Sham surgery can improve causal inference by accounting for placebo effects; however, it exposes participants to non-therapeutic surgical risks such as anesthesia, burr holes, or hardware insertion with no intended clinical benefit [26, 27]. Ensuring valid, fully informed permission in these trials is especially difficult since participants may be cognitively or emotionally vulnerable, potentially resulting in treatment misinterpretation. For sham or placebo-controlled neurosurgical designs, ethical guidelines now call for expert neuroethics assessment, iterative consent processes, and thorough risk-benefit analysis.

IV A recurring gap in neurodevice research is post-trial care and stewardship. According to several publications, participants with implanted devices frequently experience exorbitant maintenance expenditures, a lack of followup, or complete device abandonment once the trial is completed [4]. For example, adaptive DBS studies or experimental BCI implants may necessitate battery replacement, software upgrades, or clinical monitoring that are not guaranteed by sponsors or manufacturers [28]. The lack of pretrial device stewardship plans is an ethical failure, emphasizing the importance of specific contractual and regulatory commitments to ensure long-term participant engagement.

V Modern neurotechnologies, such as closed-loop DBS systems and BCIs, provide new failure modes involving brain data privacy, cybersecurity, and long-term governance. Neural signals can be stored or sent remotely, potentially exposing them to illegal access or misuse [29]. Proprietary software and hardware can compound dangers by limiting participant autonomy and long-term support, while legal frameworks for neurorights are still evolving. These examples demonstrate the significance of incorporating robust cybersecurity, continuing consent for data usage, transparency, and adherence to evolving neuroethical norms in trial design.

These typical cases highlight the numerous dangers associated with neuroscience experiments. Preclinical misprediction and dose-setting errors can quickly lead to life-threatening occurrences, as demonstrated by TGN1412 and BIA 10-2474. Ethical issues with fake surgery and consent continue to concern neurosurgical researchers. Post-trial requirements and device stewardship are not well handled, putting participants at risk. Finally, the development of neurotechnologies raises data privacy and cybersecurity problems, necessitating additional ethical, legal, and technical precautions. Addressing these hazards necessitates a systematic strategy that includes conservative trial design, ethical oversight, and long-term participant protection.

DISCUSSION

In order to reduce unforeseen toxicities, conservative first-in-human dosing strategies should include sentinel dosing with single-participant administration and adequate washout periods before cohort escalation, as well as predictive pharmacokinetic and pharmacodynamic modeling and translational biomarkers. Independent safety oversight is critical, and all high-risk, invasive, or first-in-human studies should include externally chaired Data and Safety Monitoring Boards with set stopping procedures for adverse events, as well as real-time reporting and review methods. Informed consent should be layered and iterative, combining concise summaries with extensive appendices, understanding checks, and review over time, as well as adjusting communication tactics for participants with cognitive or communication impairments to reduce therapeutic misperception. Sham therapies should only be used in situations where there are no alternatives, and they should be accompanied by a thorough neuroethics review, a full risk-benefit evaluation, intensive participant counseling, and continuous consent procedures. Post-trial device stewardship should be mandated by sponsor or manufacturer promises for long-term maintenance, battery replacement, software upgrades, and monitoring, which should be backed up by pretrial escrow or contractual guarantees. Transparency must be assured by frequent updates in public trial registries such as ClinicalTrials.gov and EUCTR, as well as complete reporting of adverse events in peerreviewed literature using de-identified participant data to foster scientific learning. To protect brain data storage, transmission, and access, robust data privacy, cybersecurity, and neurodevice governance frameworks are essential, as are emerging neurorights principles such as cognitive liberty, mental privacy, and mental integrity, which must be incorporated into trial governance. Finally, regulatory alignment should be maintained with ICHGCP, ISO 14155, ISO 14971, and any local regulations, as well as necessary investigator training in neuroethics, data security, and device-specific governance frameworks. Key areas and corresponding recommended actions are being presentable in table 2.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue I January 2026

Area	Recommended Action
First-in-Human Dosing	Sentinel dosing, stepwise escalation, translational modeling
Safety Oversight	External DSMB, predefined stopping rules, real-time AE monitoring
Consent	Layered, iterative, cognitive-adapted consent, comprehension checks
Sham Surgery	Restrict use, specialized ethics review, detailed counseling
Post-Trial Device Care	Sponsor commitment, maintenance, software/battery updates, escrow plans
Transparency	Mandatory registry updates, public adverse event reporting
Data & Cybersecurity	Secure storage/transmission, neurorights adherence, de-identification
Regulatory Alignment	ICH-GCP, ISO standards, investigator neuroethics training

Table 2. Policy Checklist

Implementing these guidelines necessitates collaboration among regulators, sponsors, investigators, and ethics committees, with a focus on long-term participant safety and ethical stewardship of developing neurotechnologies. Adopting a standardized checklist approach can help to avoid the recurring problems seen in previous and recent neuroscience trials by balancing scientific rigor with participant safety, ethical integrity, and public trust. Figure 1. Illustrates a comprehensive flow diagram representing the Corrective Framework for Neuroscience Clinical Translation.



Figure 1. Corrective Framework for Neuroscience Clinical Translation. This graphic depicts the interaction between trial phases, potential bottlenecks, and targeted remedies in neuroscience research. The Inner

Layer shows the path of research from early translational work to human testing and long-term follow-up. The Middle Layer identifies important areas of failure for each phase, such as poor model translation, safety hazards, consent obstacles, and device maintenance issues. The Outer Layer outlines corrective measures to resolve problems, including improved modeling, tighter oversight, consent standards, and public reporting. The connected arrows represent the direct path from a failure to a solution, exhibiting a closed-loop method to trial improvement.

Despite the thorough assessment of neuroscience trials, certain limitations must be recognized. First and foremost, the availability and quality of publicly published data continue to be key constraints. Many early-phase trials, especially those involving CNS-active medicines or implantable neuro-devices, underreport adverse events or just give summary data, making it difficult to adequately assess safety and efficacy. Underreporting can mask systemic risks and limit potential for cross-trial learning. Second, regulatory and

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue I January 2026

ethical variation among jurisdictions makes generalization difficult. While worldwide frameworks like ICH-GCP (ICH 2016) and ISO standards for device testing (ISO 14155, ISO 14971) offer guidelines, local implementation varies greatly. As a result, some experiments may fulfill regulatory standards in one nation but fall short in another, making direct comparisons difficult. Third, publication bias and selective reporting can skew available evidence. Trials with negative or null results are less likely to be reported, especially if the unfavorable outcomes occur in the early stages. This bias may overestimate the perceived safety or efficacy of therapies, limiting the capacity to identify recurring failure patterns systematically. Fourth, there is a growing realization in neurotherapeutics research that premature progression to in vivo and human experimentation in the absence of rigorous mechanistic validation has contributed to preventable failures and safety problems in neuroscience clinical trials. Contemporary in vitro and in silico platforms are being used to lessen reliance on animal models while allowing for comprehensive investigation of molecular mechanisms, target engagement, toxicity signals, and doseresponse relationships [30, 31]. When carefully integrated and deployed sequentially, these techniques can close crucial translational gaps that typically jeopardize first-in-human and early-phase neuroscience experiments. An organized, step-by-step pipeline from in silico modeling and in vitro validation to carefully constructed in vivo studies provides a more ethically acceptable and scientifically justifiable base before moving on to human testing [32, 33].

Furthermore, artificial intelligence-driven approaches can help at each point of the continuum by improving forecasting accuracy, detecting hidden risk signals, optimizing trial design, and strengthening decision-making. Failure to adopt such integrated and computationally informed frameworks is a continuing technological and methodological limitation in modern neuroscience clinical research. Finally, several ethical, legal, and regulatory recommendations such as post-trial device stewardship, neurorights safeguards, and cybersecurity governance continue to evolve. Enforcement procedures have not yet been standardized, and worldwide consensus on best practices is still evolving. While these guidelines are based on current literature and expert opinion, their practical application may differ between research situations.

CONCLUSION

Neuroscience trials, which include CNS-active pharmaceutical drugs, implantable neurodevices, neuromodulatory interventions, and developing cellular or gene-based therapeutics, pose novel scientific, ethical, and regulatory problems. High-profile failures, such as the TGN1412 and BIA 10 2474 Phase I studies, have highlighted ongoing issues in translating preclinical findings to humans, developing safe dosage regimens, and implementing rigorous monitoring techniques. Furthermore, ethical concerns about informed consent, sham or placebo-controlled surgical procedures, and post-trial management of brain implants highlight the intricate relationship between scientific rigor and participant welfare. This research reveals that systemic failures are rarely isolated, but rather reflect interconnected inadequacies in preclinical translation, safety oversight, ethical governance, and transparency. Underreporting of adverse events, inconsistency in regulatory regimes, and poor long-term follow-up all contribute to these hazards, limiting potential for cross-trial learning and improvement. To address these challenges, a multi-layered approach is required, including conservative first-in-human dosing with sentinel participants, independent safety monitoring boards, iterative informed consent with comprehension checks, pretrial device stewardship plans, and mandatory reporting in clinical trial registries. Emerging ethical and policy implications, such as neurorights and neuro-data governance, emphasize the changing roles of scientists, sponsors, and regulators. In the future, strong regulatory harmonization, increased trial transparency, and specialized post-trial care systems will be required to protect participants and maximize the societal value of neuroscience research. Future trials that combine scientific rigor with ethical foresight can reduce the likelihood of catastrophic adverse outcomes, protect participants' rights, and ensure that breakthrough neurology and psychiatric interventions are both safe and socially responsible. Finally, the lessons learned from previous failures must guide the design, execution, and oversight of next-generation neuroscience studies, establishing a culture of responsibility, transparency, and ethical innovation.

List of abbreviations

AE - Adverse Event

AI - Artificial Intelligence

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue I January 2026

BBB - Blood-Brain Barrier

CNS - Central Nervous System

CRS - Cytokine Release Syndrome

DBS - Deep Brain Stimulation

DSMB - Data and Safety Monitoring Board

EMA - European Medicines Agency

FDA - United States Food and Drug Administration

FIH - First-In-Human

GCP - Good Clinical Practice

ICH - International Council for Harmonization

IRB - Institutional Review Board

mAb - Monoclonal Antibody

NIH - National Institutes of Health

SAE - Serious Adverse Event

SOP - Standard Operating Procedure

Ethics Statement

This review is based on previously published scientific literature, regulatory studies, and publicly available records, including case descriptions. No new human or animal study was conducted, and no identifiable participant data were obtained. Ethical approval and informed consent were thus not required.

Conflict of Interest

The authors declare no competing interests. No author has received any financial assistance, consulting fees, or honoraria from any pharmaceutical, biotechnology, or neurotechnology commercial establishments relating to the subject matter of this review.

Author Contributions and Acknowledgements

AK conceived the study, created the conceptual framework, analyzed the literature, and wrote the original manuscript. UB contributed to the revisions, ethical analysis, and interpretation of clinical trial case studies. SK contributed to methodological design, regulatory background analysis, and manuscript review. All authors reviewed and approved the final version of the manuscript. The authors are grateful to the Department of Biotechnology, NIILM University, Kaithal, India, the Department of Pharmacology, Ram Gopal College of Pharmacy, Gurugram, India, and the Department of Pharmacology, Atam Institute of Pharmacy, OSG University, Hisar, India, for their academic and infrastructural support. The authors also thank academics and regulatory authorities for their contributions to this review, which was based on published studies and publicly available findings.

REFERENCES

1. Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody

TGN1412. The New England journal of medicine, 355(10), 1018-1028. https://doi.org/10.1056/NEJMoa063842

2. Rocha, J. F., Santos, A., Gama, H., Moser, P., Falcão, A., Pressman, P., Wallace Hayes, A., & Soares-da-
Silva, P. (2022). Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A DoubleBlind, Randomized, Placebo-Controlled Study in Healthy Volunteers. Clinical pharmacology and therapeutics, 111(2), 391-403. https://doi.org/10.1002/cpt.2290
3. Horng, S. H., & Miller, F. G. (2007). Placebo-controlled procedural trials for neurological conditions. Neurotherapeutics, 4(3), 531-536. https://doi.org/10.1016/j.nurt.2007.03.001
4. Lázaro-Muñoz, G., Pham, M. T., Muñoz, K. A., Kostick-Quenet, K., Sanchez, C. E., Torgerson, L., Robinson, J., Pereira, S., Outram, S., Koenig, B. A., Starr, P. A., Gunduz, A., Foote, K. D., Okun, M. S., Goodman, W., McGuire, A. L., & Zuk, P. (2022). Post-trial access in implanted neural device research: Device maintenance, abandonment, and cost. Brain stimulation, 15(5), 1029-1036. https://doi.org/10.1016/j.brs.2022.07.051
5. Ghooi R. B. (2011). The Nuremberg Code-A critique. Perspectives in clinical research, 2(2), 72-76. https://doi.org/10.4103/2229-3485.80371
6. Broussard, G., Rubenstein, L.S., Robinson, C. et al. Challenges to ethical obligations and humanitarian principles in conflict settings: a systematic review. Int J Humanitarian Action 4, 15 (2019). https://doi.org/10.1186/s41018-019-0063-x
7. World Medical Association (2013). World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA, 310(20), 2191-2194. https://doi.org/10.1001/jama.2013.281053
8. Tariq, M. U. (2025). The Belmont Report: Guiding Ethical Principles in Human Research. In R. Throne
(Ed.), IRB, Human Research Protections, and Data Ethics for Researchers (pp. 245-268). IGI Global Scientific Publishing. https://doi.org/10.4018/979-8-3693-3848-3.ch010
9. Bhatt A. (2023). The revamped Good Clinical Practice E6(R3) guideline: Profound changes in principles and practice! Perspectives in clinical research, 14(4), 167-171. https://doi.org/10.4103/picr.picr_184_23
10. Emami, S., & Aperce, C. (2025). The amended international health regulations: Implications and challenges for domestic legal frameworks. The International journal of health planning and management, 40(1), 234-240. https://doi.org/10.1002/hpm.3853
11. International Organization for Standardization. (2020). Clinical investigation of medical devices for human subjects - Good clinical practice (ISO Standard No. 14155:2020). ISO. ISO - International Organization for Standardization
12. International Organization for Standardization. (2019). Medical devices - Application of risk management to medical devices (ISO Standard No. 14971:2019). ISO. ISO - International Organization for Standardization
13. Yuste, R. Advocating for neurodata privacy and neurotechnology regulation. Nat Protoc 18, 2869-2875 (2023). https://doi.org/10.1038/s41596-023-00873-0
14. Attarwala, H. (2010). TGN1412: From Discovery to Disaster. Journal of Young Pharmacists, 2(3), 332-
336. https://doi.org/10.4103/0975-1483.66810
15. Moore, N. (2016). Lessons from the fatal French study BIA-10-2474. BMJ, 353, Article i2727. https://doi.org/10.1136/bmj.i2727
16. Hendriks, S., Grady, C., Ramos, K. M., et al. (2019). Ethical challenges of risk, informed consent, and posttrial responsibilities in human research with neural devices: A review. JAMA Neurology, 76(12), 1506-1514. https://doi.org/10.1001/jamaneurol.2019.3523
17. Shaheen, N., & Flouty, O. (2024). Unlocking the future of deep brain stimulation: innovations, challenges, and promising horizons. International journal of surgery (London, England), 110(6), 31463148. https://doi.org/10.1097/JS9.0000000000001279
18. Tremblay-McGaw, A. G., Hamlat, E. J., Becker, N. C., Astudillo Maya, D. A., Krystal, A. D., & Sellers, K. K. (2025). Best practices for clinical trials of deep brain stimulation for neuropsychiatric indications.Frontiers in Human Neuroscience, 19, Article 1572972. https://doi.org/10.3389/fnhum.2025.1572972

19. Johnson, S., & Goebel, A. (2023). Sham controls in device trials for chronic pain – tricky in practice: A review article. Contemporary Clinical Trials Communications, 35, Article 101203. https://doi.org/10.1016/j.conctc.2023.101203
20. Cho, H. L., Danis, M., & Grady, C. (2018). Post-trial responsibilities beyond post-trial access. The Lancet, 391(10129), 1478-1479. https://doi.org/10.1016/S0140-6736(18)30761-X
21. Mehrotra, N., & Manchikanti, P. (2024). Post-trial access to investigational drugs in India: addressing challenges in the regulatory framework. Medical law review, 32(1), 20-41. https://doi.org/10.1093/medlaw/fwad028
22. Minen, M. T., & Stieglitz, E. J. (2021). Wearables for Neurologic Conditions: Considerations for Our Patients and Research Limitations. Neurology. Clinical practice, 11(4), e537-e543. https://doi.org/10.1212/CPJ.0000000000000971
23. Muñoz, K. A., Kostick, K., Sanchez, C., Kalwani, L., Torgerson, L., Hsu, R., Sierra-Mercado, D., Robinson, J. O., Outram, S., Koenig, B. A., Pereira, S., McGuire, A., Zuk, P., & Lázaro-Muñoz, G. (2020). Researcher Perspectives on Ethical Considerations in Adaptive Deep Brain Stimulation Trials. Frontiers in human neuroscience, 14, 578695. https://doi.org/10.3389/fnhum.2020.578695
24. López Bernal, S., Huertas Celdrán, A., & Martínez Pérez, G. (2022). Neuronal Jamming cyberattack over invasive BCIs affecting the resolution of tasks requiring visual capabilities. Computers & Security, 112, Article 102534. https://doi.org/10.1016/j.cose.2021.102534
25. Kaur, R., Sidhu, P., & Singh, S. (2016). What failed BIA 10-2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials. Journal of pharmacology & pharmacotherapeutics, 7(3), 120-126. https://doi.org/10.4103/0976-500X.189661
26. Farah, M. J., Smith, M. E., & Moody, S. (2014). Brain stimulation ethics and sham-controlled designs. JAMA Psychiatry, 71(5), 543-544. https://doi.org/10.1001/jamapsychiatry.2013.4544
27. Brim, R. L., & Miller, F. G. (2012). The potential benefit of the placebo effect in sham-controlled trials: Implications for risk-benefit assessments and informed consent. Journal of Medical Ethics, 38(12), 748751.
28. Krishnamoorthy, U., Lakshmipathy, P., Ramya, M. et al. Navigating the future of healthcare with innovations and challenges in implantable battery technology for biomedical devices. Discov Appl Sci 6, 584 (2024). https://doi.org/10.1007/s42452-024-06278-2
29. Jiang, X., Fan, J., Zhu, Z., Wang, Z., Guo, Y., Liu, X., Jia, F., & Dai, C. (2023). Cybersecurity in neural interfaces: Survey and future trends. Computers in Biology and Medicine, 167, 107604. https://doi.org/10.1016/j.compbiomed.2023.107604
30. Kaushik, A., Kaushik, A., Mor, R., Kaura, S., & Sharma, S. (2023). Synthesis and characterization of Gum Acacia encapsulated Ursolic acid nanoparticles enhancing bioavailability and acetylcholinesterase inhibition for therapeutic approach of Alzheimer's disease. African Journal of Biological Sciences, 5(3), 156-169. https://afjbs.com/issue-content/synthesis-and-characterization-of-gum-acacia-encapsulatedursolic-acid-nanoparticles-enhancing-bioavailability-and-acetylcholinesterase-inhibition-for-therapeuticapproach-of-alzheimer-s-disease-8097
31. Kaushik, A., Kaura, S., & Mor, R. (2025). Synthesis and characterization of Pullulan encapsulated Ursolic acid nanoparticles for enhanced bioavailability and acetylcholinesterase inhibition in Alzheimer's disease therapy. International Journal of Pharmacy Research & Technology (IJPRT), 15(1), 124-139. https://ijprt.org/index.php/pub/article/view/334
32. Kaushik, A., Mor, R., Kaushik, A., & Kaura, S. (2025). Redefining preclinical neuroscience: AI-driven in-silico models as ethical and efficient alternatives to animal testing in Alzheimer's nanomedicine research. International Journal of Research and Scientific Innovation (IJRSI), 12(15), 2003-2016. Special Issue on Public Health. https://doi.org/10.51244/IJRSI.2025.1215000154P
33. Kaushik, A., Mor, R., & Kaura, S. (2025). The potential of Ursolic acid nanoformulations as drug delivery systems in Alzheimer's disease therapy and research. International Journal of Latest Technology in Engineering Management & Applied Science, 14(4), 795-800. https://doi.org/10.51583/IJLTEMAS.2025.140400094
34. Kaushik, A., & Mor, R. (2025). Predicting Human Neurotherapeutic Response through Preclinical Imaging Intelligence. International Journal of Research and Innovation in Applied Science (IJRIAS), 10(10). https://doi.org/10.51584/IJRIAS.2025.10100000171
35. Kaushik, A., Mor, R., Kaushik, A., Kaura, S., & Sharma, S. (2025, December). AI approach to Education and Research Acceleration in Neuroscience and Nanobiomedicine [Conference presentation]. Two Days International Multidisciplinary Conference on "Global Shifts in

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue I January 2026

Knowledge, Policy, and Practice: Multidisciplinary Approaches to Education, Innovation, and Sustainable Futures," Tantia University, Sri Ganganagar, Rajasthan, India. Retrieved from (PDF) AI approach to Education and Research Acceleration in Neuroscience and Nanobiomedicine